Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

NCT03500263 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: PTI-808
DRUG: Placebo
DRUG: PTI-801
DRUG: PTI-428
DRUG: Placebo

Sponsor

Proteostasis Therapeutics, Inc.